This indicates that the iRhom2-ADAM17 complex is a potential tumour marker for OSCC, which seems to be in line with the fact that patients with TOC mutations, which increase ADAM17 activity, have a higher risk of developing OSCC (Fig. 8). Here, ADAM17 is linked to neoplasm.